Global Primary Sclerosing Cholangitis Market 2017-2020 & 2030 Featuring Gilead Sciences, HighTide Biopharma, NGM Biopharmaceuticals, Intercept Pharmaceuticals, Dr Falk Pharma

NEXT STORY
TLC Enrolls First Subject in Phase I Clinical Trial of Inhalable Anti-COVID-19 Program (TLC19)
PREV STORY
Polyphor receives CARB-X award of up to USD 18.44 million to support development of new antibiotic program
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Cue Biopharma and LG Chem Life Sciences Announce WT1 as the Next Immuno-STAT™ Target in Oncology

   WT1 is a Well-Characterized Oncofetal Antigen, Expressed in Solid Tumors and Hematologic Malignancies CAMBRIDGE, Mass., ...

author_avatar
NASDAQ Market News

Drugs For Benign Prostatic hypertrophy Global Market Report 2021: COVID 19 Impact and Recovery to 2030

author_avatar
NASDAQ Market News

NOHO PARTNERS PLC FINANCIAL STATEMENTS RELEASE 1 JANUARY – 31 DECEMBER 2020: The year of COVID-19 caused an operating loss of MEUR 24 – following structural changes and a new financing agreement, the company prepares for a rebuilding phase

author_avatar
NASDAQ Market News